SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Falk R.J., Jennette J.C. (1988) Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. New Eng J Med 318: 16517.
  • 2
    Ara J., Mirapeix E., Rodriguez R., Saurina A., Darnell A. (1999) Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dialysis Transplantation 14: 166772.
  • 3
    Andrews B.S., Eisenberg R.A., Theofilopoulos A.N., Izui S., Wilson C.B., McConahey P.J., Murphy E.D., Roths J.B., Dixon F.J. (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148: 1198215.
  • 4
    Helyer B.J., Howie J.B. (1963) Renal disease associated with positive lupus erythematosus tests in a cross-bred strain of mice. Nature 197: 197.
  • 5
    Kinjoh K., Kyogoku M., Good R.A. (1993) Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis. Proc Natl Acad Sci USA 90: 34137.
  • 6
    Nishimoto N., Sasai M., Shima Y., Nakagawa M., Matsumoto T., Shirai T., Kishimoto T., Yoshizaki K. (2000) Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95: 5661.
  • 7
    Nishimoto N., Kanakura Y., Aozasa K., Johkoh T., Nakamura M., Nakano S., Nakano N., Ikeda Y., Sasaki T., Nishioka K., Hara M., Taguchi H., Kimura Y., Kato Y., Asaoku H., Kumagai S., Kodama F., Nakahara H., Hagihara K., Yoshizaki K., Kishimoto T. (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106: 262732.
  • 8
    Otani N., Morishita Y., Oh I., Saito O., Takemoto F., Muto S., Kusano E. (2012) Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab). Internal Med 51: 13758.
  • 9
    Yokota S., Miyamae T., Imagawa T., Iwata N., Katakura S., Mori M., Woo P., Nishimoto N., Yoshizaki K., Kishimoto T. (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52: 81825.
  • 10
    Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., Iwata N., Umebayashi H., Murata T., Miyoshi M., Tomiita M., Nishimoto N., Kishimoto T. (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371: 9981006.
  • 11
    Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Hashimoto J., Azuma J., Kishimoto T. (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 17619.
  • 12
    Kamadam H., Nakagami K. (1996) Effect of mizoribine on collagen-induced arthritis in mice. Jpn J Pharmacol 70: 16975.
  • 13
    Kamata K., Okubo M., Uchiyama T., Masaki Y., Kobayashi Y., Tanaka T. (1984) Effect of mizoribine on lupus nephropathy of New Zealand black/white F1 hybrid mice. Clin Immunol Immunopathol 33: 318.
  • 14
    Takahashi K., Oharaseki T., Nagao T., Yokouchi Y., Yamada H., Nagi-Miura N., Ohno N., Saji T., Okazaki T., Suzuki K. (2011) Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease. Pediatric Rheumatol 9: 309.
  • 15
    Hirayama K., Kobayashi M., Hashimoto Y., Usui J., Shimizu Y., Hirayama A., Yoh K., Yamagata K., Nagase S., Nagata M., Koyama A. (2004) Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kid Dis 44: 5763.
  • 16
    Tokunaga M., Tamura M., Kabashima N., Serino R., Shibata T., Matsumoto M., Miyamoto T., Miyazaki M., Furuno Y., Fujimatsu S., Muta T., Takeuchi M., Abe H., Okazaki M., Otsuji Y. (2009) A case report of steroid-resistant antineutrophil cytoplasmic antibody-related vasculitis successfully treated by mizoribine in a hemodialysis patient. Ther Aph Dial 13: 779.
  • 17
    Nishioka Y., Horita Y., Tadokoro M., Taura K., Suyama N., Miyazaki M., Harada T., Kohno S. (2006) Mizoribine induces remission of relapsed ANCA-associated renal vasculitis. Nephrol Dial Transpl 21: 10878.
  • 18
    Tomizawa K., Nagao T., Kusunoki R., Saiga K., Oshima M., Kobayashi K., Nakayama T., Tanokura M., Suzuki K. (2010) Reduction of MPO–ANCA epitopes in SCG/Kj mice by 15-deoxyspergualin treatment restricted by IgG2b associated with crescentic glomerulonephritis. Rheumatol (Oxford) 49: 124556.
  • 19
    Neumann I., Birck R., Newman M., Schnülle P., Kriz W., Nemoto K., Yard B., Waldherr R., Van Der Woude F.J. (2003) SCG/Kinjoh mice: a model of ANCA-associated crescentic glomerulonephritis with immune deposits. Kidney Int 64: 1408.
  • 20
    Saiga K., Tokunaka K., Ichimura E., Toyoda E., Abe F., Yoshida M., Furukawa H., Nose M., Ono M. (2006) NK026680, a novel suppressant of dendritic cell function, prevents the development of rapidly progressive glomerulonephritis and perinuclear antineutrophil cytoplasmic antibody in SCG/Kj mice. Arthritis Rheum 54: 370715.
  • 21
    Morse H.C., III, Davidson W.F., Yetter R.A., Murphy E.D., Roths J.B., Coffman R.L, (1982) Abnormalities induced by the mutant gene Ipr: expansion of a unique lymphocyte subset. J Immunol 129: 26125.
  • 22
    Kallen K.J. (2002) The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 1592: 32343.
  • 23
    Shivakumar S.G., Tsokos C., Datta S.K. (1989) T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 143: 10312.
  • 24
    Crispin J.C., Oukka M., Bayliss G., Cohen R.A., Van Beek C.A., Stillman I.E., Kyttaris V.C., Juang Y.T., Tsokos G.C. (2008) Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 181: 87616.
  • 25
    Ohlsson S., Wieslander J. Segelmark M. (2004) Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome? Mediat Inflamm 13: 27583.
  • 26
    Tesar V., Jirsa M., Jr., Zima T., Kalousová M., Bartunková J., Stejskalová A., Dostál C., Zabka J. (2002) Soluble cytokine receptors in renal vasculitis and lupus nephritis. Med Sci Monitor 8: BR249.
  • 27
    Romano M., Sironi M., Toniatti C., Polentarutti N., Fruscella P., Ghezzi P., Faggioni R., Luini W., van Hinsbergh V., Sozzani S., Bussolino F., Poli V., Ciliberto G., Mantovani A. (1997) Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6: 31525.
  • 28
    Hooper W.C., Phillips D.J., Evatt B.L. (1997) Endothelial cell protein S synthesis is upregulated by the complex of IL-6 and soluble IL-6 receptor. Thromb Haemost 77: 10149.
  • 29
    Marin V., Montero-Julian F.A., Grès S., Boulay V., Bongrand P., Farnarier C., Kaplanski G. (2001) The IL-6-soluble IL-6ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J Immunol 167: 343542.
  • 30
    Kitani A., Hara M., Hirose T., Harigai M., Suzuki K., Kawakami M., Kawaguchi Y., Hidaka T., Kawagoe M., Nakamura H. (1992) Autostimulatory effects of IL-6 on excessive B Cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol 88: 7583.
  • 31
    Richards H.B., Satoh M., Shaw M., Libert C., Poli V., Reeves W.H. (1998) Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 188: 98590.
  • 32
    Soga T., Ishigatsubo Y., Kitamura H., Okubo T. (1996) Effect of mizoribine on pulmonary lesions in MRL/lpr/lpr mice. Autoimmunity 25: 918.